The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

There was a slight increase in grade ≥3 drug-related adverse events in the Keytruda arm (59% vs 51% ... created and published ...

Merck's anti-PD-1 therapy, which treats patients with a certain form of lung cancer in combination with chemotherapy, is better known by its brand name Keytruda. The drug, Merck's top selling ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda ... down 1.6%. Keytruda is the world's top-selling drug and raked in about $25 ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

When bladder cancer invades nearby muscle, total removal of the organ is the standard of care A new trial finds that post-op ...